23ANDME HOLDING CO. - COMMON STOCK

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

14 May 2024 06:00:00 By Nasdaq GlobeNewswire

23andMe to Report Q4 and Full Year FY2024 Financial Results

09 May 2024 15:50:07 By Nasdaq GlobeNewswire

23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

23andMe announces CEO’s intention to pursue a potential take-private

18 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

05 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

20 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago

19 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

23andMe Launches New Genetic Reports on Common Forms of Cancer

06 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

23andMe Reports Third Quarter Fiscal 2024 Financial Results

07 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

31 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

30 Jan 2024 21:12:36 By Nasdaq GlobeNewswire

23andMe to Report FY2024 Third Quarter Financial Results

24 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts

19 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

23andMe Reports Second Quarter Fiscal 2024 Financial Results

08 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

07 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

23andMe to Report FY2024 Second Quarter Financial Results

25 Oct 2023 15:05:00 By Nasdaq GlobeNewswire